Calcii dobesilas monohydricus
The active substance of Galvenox is calcium dobesilate. The site of action of calcium dobesilate is:
the endothelium of capillaries, the walls of veins, and lymphatic vessels. The maximum concentration of the medicine in the blood is reached about 6 hours after administration.
Galvenox reduces the permeability of capillary walls, resulting in reduced exudation; increases the elasticity and tone of venous walls; reduces blood viscosity by changing the protein composition and reducing platelet aggregation; improves microcirculation, prevents blood stasis in venous vessels, and prevents thrombosis formation.
The medicine also reduces the permeability of lymphatic vessels and increases lymphatic drainage, resulting in reduced swelling.
Before starting treatment with Galvenox, discuss it with your doctor.
Contact your doctor if you have active gastric or duodenal ulcer or chronic gastritis. Periodic monitoring of gastric and duodenal function is recommended. If symptoms worsen, the medicine should be discontinued and a doctor consulted.
Consult your doctor, even if the above warnings refer to past situations.
In patients with severe renal impairment, especially those undergoing dialysis, reduced doses of the medicine should be used.
The effect of the medicine has not been studied in children under 12 years of age. The medicine should not be used in children.
Tell your doctor about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
There are no data on the interaction of the medicine with other medicines.
The medicine is taken orally during main meals.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, ask your doctor for advice before taking this medicine.
Pregnancy
Galvenox may be used in pregnant women only if the potential benefit of the medicine outweighs the possible risk to the fetus.
Breastfeeding
The medicine passes into breast milk in small amounts. There are no data on the effect of the medicine on breastfed infants.
Before starting treatment with the medicine, breastfeeding should be stopped.
Galvenox does not affect the ability to drive and use machines.
The medicine contains azorubine (E122) and quinoline yellow (E104) and may cause allergic reactions.
This medicine should always be taken exactly as advised by your doctor. If you are unsure, ask your doctor.
Usually, 1 hard capsule is taken once or twice a day (i.e., 500 mg to 1000 mg per day).
The treatment period usually lasts from several weeks to several months.
The medicine is taken orally, during main meals.
If you have taken more than the recommended dose of the medicine, contact your doctor or pharmacist.
Do not take a double dose to make up for a missed dose.
If you have any further questions on the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Rarely (in less than 1 in 1000 people, but more than 1 in 10,000 people), the following may occur:
Very rarely (in less than 1 in 10,000 people), bone marrow depression with agranulocytosis (an acute condition that may manifest as high fever, infections in the mouth or inflammatory conditions in the anus and genital organs) has been observed. In such cases, the medicine should be discontinued and a doctor consulted.
Local (rash) and generalized (urticaria) allergic reactions have been reported.
Most side effects disappear after discontinuation of Galvenox or dose reduction.
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Store below 30°C. Store in the original package to protect from moisture.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the package after EXP. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Galvenox is available in the form of hard capsules. The capsule is oval, two-part. The inner part (body) is white, the outer part (cap) is red.
The contents of the capsule are white or almost white powder.
Available packs:
30 hard capsules,
60 hard capsules,
90 hard capsules.
The pack consists of blisters made of PVC/PVDC/Aluminum in a cardboard box.
Not all pack sizes may be marketed.
Pharmaceutical Cooperative "GALENA"
ul. Dożynkowa 10
52-311 Wrocław
Poland
Phone: +48 71 710 62 01
Date of Last Revision of the Leaflet:27.04.2023
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.